Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorOSE Immunotherapeutics
About this trial
This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.
Eligibility criteria
Qualifiers
Signed and dated informed consent form (ICF) prior to any trialspecific procedures.
ECOG performance status 0-1
Patients must be affiliated to a social security system or an equivalent system, if applicable as per local regulations.
Patients expressing HLA-A2 phenotype on blood sample performed by an experienced laboratory using a validated test (PCR or NGS). Additional patients HLA-A2 negative will be included in PART C.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Part A: OSE-279 100mg
- Part A: OSE-279 300mg
- Part A: OSE-279 600mg
- Part B: OSE-279 600 mg and OSE2101
- Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive
- Part C: OSE-279 600 mg - HLA-A2 positif
- Part C: OSE-279 600 mg - HLA-A2 negative
Treatment groups
41 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov